Evaluation of multi-institutional end-to-end testing for post-operative spine stereotactic body radiation therapy.

End-to-end test Impact of metal hardware Multi-institutional phantom study Post-operative spine SBRT SABR

Journal

Physics and imaging in radiation oncology
ISSN: 2405-6316
Titre abrégé: Phys Imaging Radiat Oncol
Pays: Netherlands
ID NLM: 101704276

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 06 05 2020
revised: 18 08 2020
accepted: 22 09 2020
entrez: 18 1 2021
pubmed: 19 1 2021
medline: 19 1 2021
Statut: epublish

Résumé

Post-operative spine stereotactic body radiation therapy (SBRT) represents a significant challenge as there are many restrictions on beam geometry to avoid metal hardware as it surrounds the target volume. In this study, an international multi-institutional end-to-end test using an in-house spine phantom was developed and executed. The aim was to evaluate the impact of titanium spine hardware on planned and delivered dose for post-operative spine SBRT. Five centers performed simulation, planning and irradiation of the spine phantom, with/without titanium metal hardware (MB/B), following our pre-specified protocol. The doses were calculated using the centers' treatment planning system (TPS) and measured with radiophotoluminescent glass dosimeters (RPLDs) embedded within each phantom. The dose differences between the RPLD measured and calculated doses in the target region were within ± 5% for both phantoms studied. Differences greater than 5% were observed for the spinal cord and the out-of-the target regions due to steeper dose gradient regions that are created in these plans. Dose measurements within ± 3% were observed between RPLDs that were embedded in MB and B inserts. For the spinal cord and the out-of-target regions surrounded by metal hardware, the dose measured using RPLDs was within 3% different near the titanium screws compared to the dose measured near only the metal rods. We have successfully performed the first multi-institutional end-to-end dose analysis using an in-house phantom built specifically for post-operative spine SBRT. The differences observed between the measured and planned doses in the presence of metal hardware were clinically insignificant.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
Post-operative spine stereotactic body radiation therapy (SBRT) represents a significant challenge as there are many restrictions on beam geometry to avoid metal hardware as it surrounds the target volume. In this study, an international multi-institutional end-to-end test using an in-house spine phantom was developed and executed. The aim was to evaluate the impact of titanium spine hardware on planned and delivered dose for post-operative spine SBRT.
MATERIALS AND METHODS METHODS
Five centers performed simulation, planning and irradiation of the spine phantom, with/without titanium metal hardware (MB/B), following our pre-specified protocol. The doses were calculated using the centers' treatment planning system (TPS) and measured with radiophotoluminescent glass dosimeters (RPLDs) embedded within each phantom.
RESULTS RESULTS
The dose differences between the RPLD measured and calculated doses in the target region were within ± 5% for both phantoms studied. Differences greater than 5% were observed for the spinal cord and the out-of-the target regions due to steeper dose gradient regions that are created in these plans. Dose measurements within ± 3% were observed between RPLDs that were embedded in MB and B inserts. For the spinal cord and the out-of-target regions surrounded by metal hardware, the dose measured using RPLDs was within 3% different near the titanium screws compared to the dose measured near only the metal rods.
CONCLUSION CONCLUSIONS
We have successfully performed the first multi-institutional end-to-end dose analysis using an in-house phantom built specifically for post-operative spine SBRT. The differences observed between the measured and planned doses in the presence of metal hardware were clinically insignificant.

Identifiants

pubmed: 33458345
doi: 10.1016/j.phro.2020.09.005
pii: S2405-6316(20)30055-5
pmc: PMC7807765
doi:

Types de publication

Journal Article

Langues

eng

Pagination

61-68

Informations de copyright

© 2020 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Arjun Sahgal has received honorarium for past educational seminars from Medtronic and Elekta AB and research grants from Elekta AB. Dr. Arjun Sahgal has participated on the medical advisory board for Varian Medical Systems and Merck. Dr. Arjun Sahgal has received honorarium for past educational seminars from Accuray and Medtronic.

Références

Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):548-53
pubmed: 19765914
Med Phys. 2016 Sep;43(9):5117
pubmed: 27587042
J Neurosurg Spine. 2011 Feb;14(2):151-66
pubmed: 21184635
Med Phys. 2014 Jan;41(1):011702
pubmed: 24387494
Radiother Oncol. 2008 Feb;86(2):258-63
pubmed: 18023489
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1414-1428
pubmed: 27479724
J Appl Clin Med Phys. 2016 Jan 08;17(1):234-245
pubmed: 26894359
Med Phys. 2014 Nov;41(11):112104
pubmed: 25370655
Med Dosim. 2003 Summer;28(2):107-12
pubmed: 12804709
Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):499-507
pubmed: 30003994
Radiother Oncol. 2006 May;79(2):198-202
pubmed: 16677729
Neurosurgery. 2019 Jun 1;84(6):1242-1250
pubmed: 29796646
Phys Med Biol. 2013 Oct 7;58(19):6733-47
pubmed: 24018829
J Appl Clin Med Phys. 2016 May 08;17(3):475-485
pubmed: 27167252
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):577-83
pubmed: 16168849
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):341-7
pubmed: 22713832
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):107-16
pubmed: 20951503
Med Dosim. 2012 Spring;37(1):98-107
pubmed: 21925861
Neuro Oncol. 2013 Oct;15(10):1413-9
pubmed: 24057886
Med Phys. 2007 Jun;34(6):2119-32
pubmed: 17654915

Auteurs

Tomohisa Furuya (T)

Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 1138677 Tokyo, Japan.

Young K Lee (YK)

Department of Radiation Oncology, Sunnybrook Odette Cancer Center, University of Toronto, M4N 3M5 Toronto, Ontario, Canada.

Ben R Archibald-Heeren (BR)

Radiation Oncology Centres, Sydney Adventist Hospital, Wahroonga, NSW 2076, Australia.

Mikel Byrne (M)

Radiation Oncology Centres, Sydney Adventist Hospital, Wahroonga, NSW 2076, Australia.

Bruno Bosco (B)

Radiation Oncology Centres, Sydney Adventist Hospital, Wahroonga, NSW 2076, Australia.

Jun H Phua (JH)

Department of Radiation Oncology, National Cancer Center Singapore, 169610 Singapore, Singapore.

Hidetoshi Shimizu (H)

Department of Radiation Oncology, Aichi Cancer Center Hospital, 4648681 Aichi, Japan.

Shimpei Hashimoto (S)

Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 1138677 Tokyo, Japan.

Hiroshi Tanaka (H)

Department of Radiation Oncology, Aichi Cancer Center Hospital, 4648681 Aichi, Japan.

Arjun Sahgal (A)

Department of Radiation Oncology, Sunnybrook Odette Cancer Center, University of Toronto, M4N 3M5 Toronto, Ontario, Canada.

Katsuyuki Karasawa (K)

Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 1138677 Tokyo, Japan.

Classifications MeSH